
News • Antisense therapy update
Huntington's disease: setback for study of promising agent
Roche announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen (previously IONIS-HTTRx and RG6042) in manifest Huntington’s disease (HD). The decision was based on the results of a pre-planned review of the data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). The iDMC made its recommendation based on the…